EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: Findings from the CAMPOS-TAVI study

Jérôme Costa, Ahmed El-Ali, David Morland, Sebastien Dejust, Dimitri Papathanassiou, Pierre Nazeyrollas, Damien Metz

Archives of Cardiovascular Diseases · 2024

DOI: 10.1016/j.acvd.2024.04.007 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Archives of Cardiovascular Diseases, 2024. Verfasst von Jérôme Costa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, University Hospital of Reims, rue du Général-Koenig, 51100 Reims, France. Electronic address: jcosta@chu-reims.fr. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Pfizer France, Ramsay Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) can manifest as rhythm disorders, heart failure, but also valvular degeneration. Despite aortic stenosis (AS) being prevalent among the elderly, data on ATTR-CM prevalence and outcome in patients with AS undergoing transaortic valve implantation (TAVI) remain scarce. AIM: To determine ATTR-CM prevalence and evaluate 1-year survival in patients undergoing TAVI. METHODS: Between December 2020 and September 2021, 100 consecutive patients underwent TAVI and were screened prospectively for ATTR-CM using bone scintigraphy (BS). Monoclonal gammopathy was ruled out in case of cardiac uptake on BS. All patients were followed prospectively for 1year after TAVI. RESULTS: The proportion of patients aged≥75years or with a EuroSCORE II>8% and possible femoral access was 99%. The abnormal cardiac uptake rate on BS was 7% (95% confidence interval: 2-12%); 86% of these patients were male. The RAISE (remodelling, age, injury, system and electrical) score, indicative of ATTR-CM risk, was higher in case of positive BS (P=0.04). Patients with positive BS were older and exhibited wider QRS complexes on electrocardiography (P=0.003), a higher frequency of reduced LVEF (57% vs. 17%), impaired basal LV strain (P=0.02) and a lower voltage/mass ratio (P=0.01). History of pacemaker implantation before TAVI was higher in the positive BS group (P=0.0004) and remained the only statistically significant factor after adjustment using the Holm-Bonferroni method. One-year survival of patients with positive BS did not differ from that of patients with isolated AS. CONCLUSIONS: Prevalence of ATTR-CM in patients treated with TAVI, underscoring the need for continued surveillance for potential development of ATTR-CM after TAVI. Caution is warranted regarding the 1-year survival because of the lack of study power. Further investigations are needed to define long-term prognosis of AS with ATTR-CM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisTranscatheter Aortic Valve ReplacementAmyloid Neuropathies, FamilialCardiomyopathiesHumansMaleFemalePrevalenceAgedAged, 80 and overTime FactorsTreatment OutcomeRisk FactorsProspective StudiesRisk AssessmentAortic Valve

Stichwörter der Autor:innen

Amyloid transthyretin cardiomyopathyBone scintigraphyHeart failureSevere aortic stenosisTransaortic valve implantation

Autor:innen und Institutionen

  • Cardiology Department, University Hospital of Reims, rue du Général-Koenig, 51100 Reims, France. Electronic address: jcosta@chu-reims.fr.
  • Cardiology Department, University Hospital of Reims, rue du Général-Koenig, 51100 Reims, France.
  • Service de Médecine Nucléaire, Institut Godinot, 51100 Reims, France; Laboratoire de Biophysique, UFR de Médecine, Université de Reims Champagne-Ardenne, 51100 Reims, France; CReSTIC UR 3804, Université de Reims Champag…
  • Service de Médecine Nucléaire, Institut Godinot, 51100 Reims, France.
  • Cardiology Department, University Hospital of Reims, rue du Général-Koenig, 51100 Reims, France; Laboratoire de recherche en Santé Publique, Vieillissement, Qualité de vie et Réadaptation des Sujets Fragiles, EA 3797, U…

Förderung

  • Pfizer France
  • Ramsay Santé

Zitieren

APA

Costa, J., El-Ali, A., Morland, D., Dejust, S., Papathanassiou, D., Nazeyrollas, P., & Metz, D. (2024). Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: Findings from the CAMPOS-TAVI study. Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2024.04.007

Vancouver

Costa J, El-Ali A, Morland D, Dejust S, Papathanassiou D, Nazeyrollas P, et al. Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: Findings from the CAMPOS-TAVI study. Archives of Cardiovascular Diseases. 2024. doi:10.1016/j.acvd.2024.04.007

BibTeX
@article{Costa2024,
  author = {Costa, Jérôme and El-Ali, Ahmed and Morland, David and Dejust, Sebastien and Papathanassiou, Dimitri and Nazeyrollas, Pierre and Metz, Damien},
  title = {Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: Findings from the CAMPOS-TAVI study},
  journal = {Archives of Cardiovascular Diseases},
  year = {2024},
  doi = {10.1016/j.acvd.2024.04.007}
}
Kostenlos starten →